Chemotherapy before surgery for triple-negative breast cancer
Part of Cancer clinical trials.
This trial tests whether giving chemotherapy before surgery helps women with triple-negative breast cancer that is still local (not spread far). The goal is to see if this neoadjuvant approach improves outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 65 years old.
- You have been diagnosed with triple-negative breast cancer (tumor tests negative for estrogen, progesterone, and HER2 receptors).
- The cancer has not spread to distant parts of the body, and it can be completely removed with surgery.
- You have no significant nerve damage, heart problems, or other serious uncontrolled medical conditions.
- Your blood counts, liver, and kidney function are within acceptable levels for chemotherapy.
- If you could become pregnant, you agree to use effective contraception during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a combination of chemotherapy drugs (nab-paclitaxel and carboplatin) plus an immunotherapy drug (PD1 inhibitor) given before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by using these treatments before the main surgery.
This trial tests a new drug combination given before surgery for triple-negative breast cancer. The drugs include an immunotherapy medication (AK112) and standard chemotherapy, and the goal is to see if it helps shrink the tumor and improve outcomes.
This trial compares two different chemotherapy combinations given before surgery (neoadjuvant therapy) for people with triple-negative breast cancer. It looks to see which drug combination works better to control the cancer before and around the time of the operation.
This trial tests a new combination of chemotherapy and immunotherapy that avoids a class of drugs called anthracyclines, which can be hard on the heart. The goal is to shrink tumors before surgery for people with triple-negative or low-hormone-receptor breast cancer.
This trial tests whether adding an immunotherapy drug (camrelizumab) to standard chemotherapy before surgery can improve outcomes for women with early-stage triple-negative breast cancer. The treatment is given before surgery to shrink tumors and may help prevent the cancer from coming back.
This trial tests whether giving pembrolizumab (an immunotherapy drug) together with chemotherapy before surgery can help treat early-stage triple-negative breast cancer. It aims to improve outcomes by shrinking the tumor before removal.
Hear when a new Triple Negative Local Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.